Business Context and Reporting Period
This Form 8-K is filed by BioSig Technologies, Inc. (not Streamex Corp.) on April 29, 2016. The report details the consummation of five additional closings under a Unit Purchase Agreement dated October 23, 2015, involving the sale of unregistered equity securities to accredited investors.
Key Financial Metrics
- Recent Proceeds: $2,634,515.50 raised from the issuance of 1,756,344 additional units.
- Total Proceeds (Cumulative): $4,504,515.50 raised across all closings under the Purchase Agreement.
- Securities Issued: 1,756,344 units (comprising one share of Common Stock and a warrant to purchase 0.5 shares per unit).
- Warrant Terms: Investor warrants are exercisable at $1.95 per share.
- Transaction Costs: Approximately $257,956 in cash compensation paid to the placement agent (Laidlaw & Company (UK) Ltd.), plus warrants to purchase 232,959 shares at $1.50 per share.
Note: The filing does not provide data on revenue, profit, cash flow, operating margins, debt levels, or general liquidity beyond the specific proceeds from this equity offering.
Material Changes
The primary material change is the increase in outstanding equity and cash reserves resulting from the five additional closings between February 9, 2016, and April 29, 2016. This follows five prior closings between October 2015 and December 2015. The total number of units issued under the agreement has increased from 1,246,666 to 3,003,010 (1,246,666 initial + 1,756,344 additional).
Outlook, Risks, and Unusual Items
- Regulatory Status: Securities were sold pursuant to Section 4(a)(2) and Regulation D (Rule 506) exemptions from registration under the Securities Act of 1933.
- Investor Qualification: All purchasers represented they were accredited investors.
- Registration Rights: Additional investors became parties to the existing Registration Rights Agreement.
- Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding future operations or financial performance.
Investor Verification Checklist
- Verify the total number of outstanding shares and warrants post-issuance to assess dilution impact.
- Confirm the company's current cash position and burn rate to determine runway provided by the $4.5M total proceeds.
- Review the full text of the Unit Purchase Agreement and Registration Rights Agreement filed as exhibits to the October 29, 2015, 8-K.
- Check for any subsequent filings regarding the use of proceeds or changes in the company's capital structure.